成纤维细胞生长因子23 在肾性贫血中的研究进展  

Research progresses in fibroblast growth factor 23 in chronic kidney disease related anemia

作　　者：顾佳雨 戴兵 GU Jiayu;DAI Bing(Department of Nephrology,Changzheng Hospital,Second Military Medical University,Shanghai 200003,China)

机构地区：[1]海军军医大学长征医院肾内科,上海200003

出　　处：《中国血液净化》2022年第4期276-279,共4页Chinese Journal of Blood Purification

基　　金：上海市临床重点专科(shslczdzk02503);国家自然科学基金面上项目(81970640)。

摘　　要：慢性肾脏病(chronic kidney disease,CKD)发病率高,早期起病隐匿,可逐渐进展为终末期肾衰竭,依赖于透析和移植治疗,医疗费用高昂,已成为严重威胁人类健康的社会公共卫生问题。CKD晚期常伴随不同程度钙磷代谢紊乱、贫血、继发性甲状旁腺功能亢进、心血管疾病等并发症。大量研究发现,成纤维细胞生长因子23(fibroblast growth factor 23,FGF23)除了参与人体内的钙磷调节外,同时影响着CKD患者红细胞的生成。FGF23的深入研究有望为临床治疗肾性贫血带来新的突破。The incidence of chronic kidney disease(CKD)is high.CKD is insidious at the early stage and may evolve gradually to end-stage renal disease(ESRD),at which patients have to rely on dialysis or kidney transplantation with a heavy financial burden.CKD has become a social and public problem that seriously threatens public health.CKD patients at late stage are often accompanied by various degrees of calcium and phosphorus metabolic disorders,anemia,secondary hyperparathyroidism,cardiovascular disease and others.Many studies have found that fibroblast growth factor 23(FGF23)is involved in the regulation of calcium and phosphorus metabolism as well as in erythropoiesis in CKD patients.Further studies on FGF23 may bring a breakthrough in the clinical treatment of anemia in CKD patients.

关 键 词：慢性肾脏病 成纤维细胞生长因子23 贫血 低氧诱导因子 

分 类 号：R45[医药卫生—治疗学]